Dr. Pollack is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
675 N St Clair St
Suite 21-100
Chicago, IL 60611Phone+1 312-695-0990Fax+1 312-695-1144
Summary
- I am a medical oncologist and specialize in treating adult patients with sarcoma. My research is focused on the development of novel immunotherapies for patients with advanced sarcoma, particularly Synovial Sarcoma (SS) and Myxoid/Round Cell Liposarcoma (MRCL). My patient care philosophy is to provide care centered on my patients goals and desires and to fight as hard as I can to help cure my patients.
Education & Training
- University of WashingtonFellowship, Hematology and Medical Oncology, 2008 - 2010
- George Washington UniversityResidency, Internal Medicine, 2005 - 2008
- George Washington University School of Medicine and Health SciencesClass of 2005
- Haverford CollegeBachelor of Arts, Mathematics, 1995 - 1999
Certifications & Licensure
- IL State Medical License 2020 - 2026
- WA State Medical License 2008 - 2022
- VA State Medical License 2005 - 2008
- DC State Medical License 2005 - 2007
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Sig Kohl Legacy Award Northwest Sarcoma Foundation, 2017
Clinical Trials
- Autologous T Cells and Cyclophosphamide in Treating Patients With Soft Tissue Sarcoma That is Metastatic or Cannot Be Removed By Surgery Start of enrollment: 2012 Jan 01
- Recombinant Interferon Gamma in Treating Patients With Soft Tissue Sarcoma Start of enrollment: 2013 Sep 25
- NY-ESO-1 Specific T Cells After Cyclophosphamide in Treating Patients With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma Start of enrollment: 2014 Jul 01
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsMelanoma-associated antigen A4: A cancer/testis antigen as a target for adoptive T-cell receptor T-cell therapy.Gabrielle Knafler, Alan L Ho, Kathleen N Moore, Seth M Pollack, Jean-Marc Navenot
Cancer Treatment Reviews. 2025-03-01 - Paradoxical Response to Neoadjuvant Therapy in Undifferentiated Pleomorphic Sarcoma: Increased Tumor Size on MRI Associated with Favorable Pathology.Mariam H Goreish, Nicolò Gennaro, Laetitia Perronne, Gorkem Durak, Amir A Borhani
Cancers. 2025-02-27 - Durable response to treatment of an atypical desmoplastic small round cell tumor with enfortumab-vedotin.John S Wang, Jack C Shapiro, Sarah Orlando, Rusul Al-Marayaty, Farres Obeidin
Journal of Cancer Research and Clinical Oncology. 2025-02-10
Press Mentions
- Exploring the Use of Weakened Viruses for Cancer TreatmentJune 12th, 2024
- SCCA’s Immunotherapy Leaders Featured at the American Society of Clinical Oncology (ASCO) Annual MeetingMay 31st, 2018
- Can You Vaccinate Yourself Against Cancer?February 21st, 2018
- Join now to see all
Grant Support
- Improving Mucosal Melanoma Therapy by Harnessing the Immunogenicity of r3LCMVNORTHWESTERN UNIVERSITY AT CHICAGO2025–2029
- Special Public T Cell Receptor Sequences that Predict Outcomes for Cancer PatientsNORTHWESTERN UNIVERSITY AT CHICAGO2023–2025
- Novel IL-12 Gene Delivery Vehicles for Transformation of Solid TumorsNORTHWESTERN UNIVERSITY AT CHICAGO2019–2024
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: